Investment Rating - The report does not explicitly provide an investment rating for WuXi AppTec [2][3]. Core Insights - The report highlights three major catalysts that may drive WuXi AppTec's stock performance in Q1 2026: 1) Updates from the industry summit scheduled for January 12-15, which is expected to support the CRO industry's outlook; 2) The release of the 1260H list in January-February 2026, which should alleviate the impact of pending policy decisions; 3) The company's full-year guidance for 2026, to be announced in March 2026 [5]. - The report indicates that in 2026, the focus for the Chinese healthcare sector will shift towards earnings realization rather than valuation multiple expansion, with WuXi AppTec expected to lead in visibility of earnings growth [7]. - The report anticipates a recovery in outsourcing demand in 2026 due to the resolution of policy and tariff uncertainties, which had previously delayed biotech financing and new R&D initiatives in 2025 [6]. Summary by Sections Company Overview - WuXi AppTec is a global enterprise with operations across Asia, Europe, and North America, providing a comprehensive range of R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire drug development cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Stock Information - Stock price as of January 5, 2026: 104.2 HKD - Market capitalization: 40.33 billion USD - Consensus target price (Refinitiv): 130.76 HKD [13].

研究报告 Research Report 8 Jan 2026 毛戈平 Mao Geping Cosmetics (1318 HK) 近况更新：25 年业绩稳健，与全球领先消费投资机构签署战略合作框架协议 Recent Update: Strong 2025 Results, Strategic Partnership Signed with Global Consumer Investment Leader [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$87.95 目标价 HK$108.20 HTI ESG 3.1-3.4-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$23.03bn / US$2.96bn 日交易额 (3 个月均值) US$16.09mn 发行股票数目 261.84mn 自由流通股 (%) 41% 1 年股价最高最低值 HK$127.50- ...

证券研究报告 | 公司深度报告 2026 年 01 月 08 日 先瑞达医疗-B（06669.HK） 波科赋能海外可期，新产品带来增长 消费品/生物医药 先瑞达是国内领先的专注于提供泛血管介入综合解决方案的创新医疗器械平台 型企业，率先于国内推出首款膝上及膝下 DCB 产品，在外周介入领域处于领先 地位；2025 年 12 月公司与控股股东波士顿科学签署新的三年期合作协议，在 产品全球商业化、制造服务和研发等领域开展一系列合作。 ❑ 与波科签署新三年期合作协议，海外放量确定性强。2023 年 2 月全球微创介 入医疗器械领先企业波士顿科学成为先瑞达控股股东，持股 65%，并于 2023 年 6 月签署首个合作谅解备忘录；2025 年 12 月，公司与波科签署新的三年 合作协议（2026-2028）：1）全球商业化：共享波科覆盖全球的渠道资源， 预计 2026-2028 年向波科销售产品交易金额上限为 3000/6200/7800 万美元； 2）产品制造：基于先瑞达智造能力提供产品 OEM 服务，预计 2026-2028 年 向波科提供制造服务交易金额上限为 100/100/300 万美元；3）产品研发：互 相 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [5]. Core Insights - The company has received approval for its innovative drug, Ruira Fup α, which is a dual-function fusion protein targeting PD-L1 and TGF-βRII, marking it as the first of its kind to be approved in the market [5][8]. - The company has a robust pipeline with over 300 new drugs under development, and it is expected to launch 7 new drugs by 2025, with Ruira Fup α being approved at the start of 2026 [8]. - The company is actively pursuing business development (BD) transactions, with expected revenues from these deals exceeding USD 16 billion, which will significantly enhance profitability [8]. - Projected net profits for the company are estimated at RMB 10.1 billion, RMB 9.1 billion, and RMB 10.4 billion for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 59.3%, -9.9%, and 14.5% [10]. Financial Summary - The company’s revenue is projected to grow from RMB 22.82 billion in 2023 to RMB 45.40 billion by 2027, reflecting a strong growth trajectory [12]. - The earnings per share (EPS) are expected to be RMB 1.52, RMB 1.37, and RMB 1.57 for the years 2025, 2026, and 2027 respectively, with a notable increase in 2025 [10]. - The company’s net profit margin is projected to be 18.5% in 2025, decreasing to 16.5% in 2026, and recovering to 17.5% in 2027 [10].

Investment Rating - The report does not provide a specific investment rating for the company [1]. Core Insights - MiniMax is positioned as a benchmark for AI expansion in China, focusing on multi-modal development to build competitive large models for the global market [7]. - The company has adopted a dual-driven business model (ToC and ToB), with consumer products generating significant cash flow and enterprise services providing high margins [7]. - MiniMax's revenue is projected to grow significantly, with estimates of $80.88 million in 2025 and $398.66 million in 2027, reflecting a compound annual growth rate of over 130% [7]. - The company has a strong global execution capability, with products covering over 2.12 billion personal users and more than 100,000 enterprise clients across 200 countries [7]. Summary by Sections Company Overview - MiniMax was established in December 2021, focusing on general AI technology development and aiming for global market presence [12]. - The company has raised over $1.5 billion in funding, with notable investors including Alibaba and Xiaomi, which supports its high R&D intensity [12][13]. - As of September 2025, MiniMax has a workforce of 385 employees, predominantly young and tech-focused, enhancing its execution efficiency [12]. Business Model - The company operates a dual-driven model, with consumer business leading in scale and cash flow, while developer enterprise business supports high margins [30]. - Consumer products include Talkie and Hailuo AI, which have shown strong performance in overseas markets, particularly in North America [31][34]. - Developer enterprise business generates revenue through API calls and model licensing, with a significant increase in paid clients from 400 in 2024 to approximately 2,500 in 2025 [39]. Technology Route and Competitive Advantages - MiniMax's core technology strategy is based on a multi-modal architecture, focusing on language, vision, and speech models [43]. - The company emphasizes a system engineering approach, ensuring high efficiency in model training and deployment [44][46]. - MiniMax's ability to rapidly iterate and improve its models positions it favorably against competitors, as it can unlock new application scenarios with each model upgrade [47][48].

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [9]. Core Insights - The company has a diverse pipeline with four proprietary ADC platforms, covering third-generation ADCs, bispecific ADCs, and immune-modulating ADCs, which have been validated through pipeline assets and recognized by multinational pharmaceutical companies like BioNTech [9][3]. - The projected revenues for 2025, 2026, and 2027 are estimated at 15.03 billion, 16.57 billion, and 17.60 billion CNY respectively, with EPS expected to improve from -15.45 CNY in 2025 to -3.40 CNY in 2027 [9][21]. - The company has made significant progress in clinical trials, with promising data from various studies, including DB-1311 showing a 42.3% objective response rate in prostate cancer and gynecological tumors, and DB-1303 achieving primary endpoints in breast cancer trials [12][15][17]. Financial Summary - The company's revenue for 2023 is reported at 1,786.54 million CNY, with an expected increase to 1,941.26 million CNY in 2024, followed by a decline to 1,503.20 million CNY in 2025 [21]. - The net profit attributable to the parent company is projected to be -1,050.43 million CNY in 2024, worsening to -1,381.48 million CNY in 2025, before improving to -468.21 million CNY in 2026 and -304.33 million CNY in 2027 [21]. - The company’s total assets are expected to reach 3,867 million CNY in 2024, with total liabilities of 1,283 million CNY, indicating a significant leverage position [21]. Pipeline Development - The company is advancing multiple clinical projects, with DB-1311 and DB-1303 showing strong efficacy in late-stage trials for various cancers, including prostate and breast cancer [12][15][17]. - DB-1305 is positioned well in the competitive landscape, with promising data in non-small cell lung cancer and triple-negative breast cancer, indicating potential for new treatment options [17]. - The company has established collaborations with six global pharmaceutical companies, with a total transaction value exceeding 6 billion USD, enhancing its commercialization pathway [3].

Investment Rating - The report maintains an "Outperform" rating for the company [2][5]. Core Insights - The company is expected to see significant revenue growth in Q4 2025, with projected revenue of 625 billion RMB and adjusted net profit of 22.6 billion RMB. The focus for 2025 will be on revenue growth and investment, particularly in integrated supply chain and instant delivery services [5]. - The management has undergone changes aimed at enhancing high-value business segments, which is expected to drive steady revenue growth and improve profits in 2026 [5]. - The adjusted net profit forecasts for 2025-2027 have been revised downwards to 76.23 billion, 87.76 billion, and 99.45 billion RMB respectively, reflecting a short-term cost increase due to investments in resources [5]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 166.625 billion RMB - 2024: 182.838 billion RMB - 2025E: 216.118 billion RMB - 2026E: 243.312 billion RMB - 2027E: 267.780 billion RMB - Year-on-year growth rates for revenue are projected at: - 2023: 21.27% - 2024: 9.73% - 2025E: 18.20% - 2026E: 12.58% - 2027E: 10.06% [4][6]. - Adjusted net profit forecasts are as follows: - 2023: 2.761 billion RMB - 2024: 7.917 billion RMB - 2025E: 7.623 billion RMB - 2026E: 8.776 billion RMB - 2027E: 9.945 billion RMB - Year-on-year growth rates for adjusted net profit are projected at: - 2023: 218.79% - 2024: 186.75% - 2025E: -3.71% - 2026E: 15.13% - 2027E: 13.31% [4][6].

证券研究报告·海外公司深度·汽车(HS) 博泰车联（02889.HK） 软硬云协同筑壁垒，AI 赋能打开成长空间 2026 年 01 月 08 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,496 | 2,557 | 3,458 | 5,452 | 7,839 | | 同比(%) | 22.83 | 70.94 | 35.24 | 57.66 | 43.78 | | 归母净利润（百万元） | (283.89) | (541.24) | (201.02) | 9.57 | 1,002.36 | | 同比(%) | 37.21 | (90.65) | 62.86 | 104.76 | 10,373.30 | | EPS-最新摊薄（元/股） | (1.89) | (3.61) | (1.34) | 0.06 | 6.68 | | P/E（现价&最新摊薄） | (109.37) | (57.37) | (154 ...

Investment Rating - The investment rating for JD Logistics is maintained at "Outperform" [2] Core Insights - The report anticipates a significant revenue increase in Q4 2025, projecting revenue of 62.5 billion RMB and an adjusted net profit of 2.26 billion RMB. The company is focusing on revenue growth and investment, particularly in integrated supply chain and instant delivery services, which are expected to drive high revenue growth in Q4 2025 [9] - The management restructuring and increased investment in high-end e-commerce and valuable business scenarios are expected to improve profits in 2026. The company is enhancing its service capabilities and optimizing its business structure, which is expected to strengthen its competitive advantage [9] - The profit forecast has been adjusted downward, with expected adjusted net profits for 2025-2027 revised to 76.23 billion, 87.76 billion, and 99.45 billion RMB respectively, reflecting a year-on-year growth of -3.71%, +15.13%, and +13.31% [9] Financial Data and Profit Forecast - Revenue projections for JD Logistics are as follows: - 2023: 166.625 billion RMB - 2024: 182.838 billion RMB - 2025E: 216.118 billion RMB - 2026E: 243.312 billion RMB - 2027E: 267.780 billion RMB - Adjusted net profit forecasts are: - 2023: 2.761 billion RMB - 2024: 7.917 billion RMB - 2025E: 7.623 billion RMB - 2026E: 8.776 billion RMB - 2027E: 9.945 billion RMB - The report indicates a significant increase in adjusted net profit for 2023 compared to 2022, with a growth rate of 218.79% [8][10]